| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Autobiography |
| Article Title |
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Andrea L Inghilesi, Donatella Gallori, Lorenzo Antonuzzo, Paolo Forte, Daniela Tomcikova, Umberto Arena, Stefano Colagrande, Silvia Pradella, Bernardo Fani, Elena Gianni, Luca Boni, Giacomo Laffi, Francesco Di Costanzo and Fabio Marra |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Associazione Italiana per la Ricerca sul Cancro (AIRC) |
|
| Istituto Toscano Tumori (ITT) |
to Marra F |
|
| Corresponding Author |
Fabio Marra, MD, PhD, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Largo Brambilla 3, I-50134 Florence, Italy. fabio.marra@unifi.it |
| Key Words |
Hepatocellular carcinoma; Sorafenib; Cirrhosis; Adverse events; Barcelona Clinic Liver Cancer |
| Core Tip |
The study provides information on the clinical characteristics and laboratory findings that predict survival in patients with hepatocellular carcinoma and established cirrhosis treated with sorafenib. This group of patients is particularly fragile and difficult to treat, and therapy with systemic agents, including sorafenib, requires careful monitoring. We report that parameters related to the tumor (extrahepatic spread, vascular invasion), common laboratory tests (alpha-fetoprotein or alkaline phosphatase) and patients characteristics (performance status) are significant predictors of overall survival in this group. These data provide important clinical information for the management of this type of patients. |
| Publish Date |
2014-02-19 16:57 |
| Citation |
Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di Costanzo F, Marra F. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2014; 20(3): 786-794 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i3/786.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i3.786 |
